OAM
BCRX icon

Oberweis Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Oberweis Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-24,000
Closed -$114K – 222
2018
Q1 		$114K Sell
24,000
-6,600
-22% -$33.9K 0.03% 222
2017
Q4 		$150K Buy
30,600
+13,500
+79% +$65.4K 0.04% 229
2017
Q3 		$90K Hold
17,100
– – 0.03% 164
2017
Q2 		$95K Hold
17,100
– – 0.03% 138
2017
Q1 		$144K Buy
+17,100
New +$119K 0.04% 138

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Oberweis Asset Management's BCRX Position: Q2 2018 in Review

Oberweis Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2018, closing a stake of 24,000 shares — an estimated $114K sold.

Oberweis Asset Management first reported a position in BCRX in Q1 2017 and held it in 5 quarters. The position peaked at $150K in Q4 2017. 103 funds tracked by Wall St. Rank hold BCRX as of Q2 2018.

  • Oberweis Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Oberweis Asset Management sold 24,000 BioCryst Pharmaceuticals shares in Q2 2018, an estimated $114K.
  • Oberweis Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2017 and held it in 5 quarters.
  • Oberweis Asset Management's BioCryst Pharmaceuticals position peaked at $150K in Q4 2017.
  • 103 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2018.

Based on Oberweis Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.